Iliana Arellano, MD
Cardiovascular Disease · Houston, TXNPI 1710917794
Payments from drug & device makers
Across 254 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$974
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$901
- Johnson & Johnson$485
- Cvrx, Inc.$343
- Medtronic$198
- Daiichi Sankyo Inc.$186
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,042100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 61 | $974 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 40 | $901 |
| Johnson & Johnson | 26 | $485 |
| Cvrx, Inc. | 12 | $343 |
| Medtronic | 7 | $198 |
| Daiichi Sankyo Inc. | 8 | $186 |
| Lexicon Pharmaceuticals, Inc. | 8 | $165 |
| Actelion Pharmaceuticals US, Inc. | 8 | $157 |
| Amgen | 8 | $155 |
| Pfizer | 7 | $143 |
| Alnylam Pharmaceuticals Inc. | 6 | $137 |
| AstraZeneca(2 entities) | 8 | $132 |
| Scpharmaceuticals Inc. | 5 | $87 |
| Esperion Therapeutics, Inc. | 6 | $85 |
| Inspire Medical Systems, Inc. | 3 | $83 |
| Bayer | 4 | $82 |
| Atricure, Inc. | 2 | $56 |
| Bardy Diagnostics, Inc. | 3 | $52 |
| Amicus Therapeutics, Inc. | 2 | $46 |
| Amarin Pharma, Inc. | 2 | $46 |
| Merck | 2 | $43 |
| Abbott | 3 | $43 |
| Bolton Medical Inc | 2 | $41 |
| Surmodics, Inc. | 2 | $40 |
| Baxter Healthcare | 2 | $40 |
| Itamar Medical Inc | 1 | $37 |
| United Therapeutics Corporation | 2 | $32 |
| Irhythm Technologies, Inc. | 1 | $29 |
| Tactile Systems Technology Inc | 2 | $28 |
| Boston Scientific | 2 | $27 |
| Solventum Corporation | 1 | $25 |
| Smith+Nephew | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Biotronik Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| ZOLL Circulation Inc | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,042 in reported general payments places this provider in the 55th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 323 | $388,873 |
| EntrestoSacubitril/Valsartan | 149 | $162,037 |
| XareltoRivaroxaban | 74 | $67,860 |
| Repatha SureclickEvolocumab | 39 | $45,288 |
| FarxigaDapagliflozin Propanediol | 37 | $43,611 |
| Ambrisentan | 11 | $17,941 |
| BrilintaTicagrelor | 22 | $17,716 |
| Metoprolol Succinate | 693 | $10,035 |
| Rosuvastatin Calcium | 737 | $9,863 |
| VascepaIcosapent Ethyl | 17 | $8,711 |
| Nebivolol Hcl | 133 | $8,687 |
| Praluent PenAlirocumab | 18 | $8,635 |
| Ranolazine ErRanolazine | 74 | $7,547 |
| CorlanorIvabradine Hcl | 13 | $6,601 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $6,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $143 | $388,873323 claims |
| NovartisEntresto | $974 | $162,037149 claims |
| Johnson & JohnsonXarelto | $485 | $67,86074 claims |
| AstraZenecaFarxiga, Brilinta | $132 | $61,32659 claims |
| AmgenCorlanor | $155 | $6,60113 claims |
| Esperion Therapeutics, Inc.Nexlizet | $85 | $6,42812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- James FeldmanHouston$3.1M
- Aditya SamalHouston$2.6M
- Pranav LoyalkaHouston$2.4M
- Anwar AhmadHouston$1.4M
- Reynolds DelgadoHouston$1.1M
- Richard SmallingHouston$908K
- Amin KarimHouston$853K
- Stephen LittleHouston$806K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.